Nisa Investment Advisors
TLX

Nisa Investment Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Nisa Investment Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$622 Buy
+65
New +$495 ﹤0.01% 2829

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Nisa Investment Advisors's TLX Position: Q1 2026 in Review

Nisa Investment Advisors opened a new position in Telix Pharmaceuticals (TLX) in Q1 2026: 65 shares worth $622. The stake represents ﹤0.01% of the portfolio and ranks #2829 among its holdings.

39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Nisa Investment Advisors held 65 shares of Telix Pharmaceuticals worth $622 as of Q1 2026.
  • Telix Pharmaceuticals was a new Nisa Investment Advisors position in Q1 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2829 holding.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.